TCIM
DRNA

TIAA CREF Investment Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

TIAA CREF Investment Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.41M Sell
96,414
-731
-0.8% -$8.4K ﹤0.01% 2162
2018
Q4 		$1.04M Buy
97,145
+9,429
+11% +$124K ﹤0.01% 2267
2018
Q3 		$1.34M Sell
87,716
-10,947
-11% -$159K ﹤0.01% 2316
2018
Q2 		$1.21M Buy
+98,663
New +$1.24M ﹤0.01% 2410
2016
Q2 		– Sell
-53,105
Closed -$285K – 3212
2016
Q1 		$285K Sell
53,105
-24,542
-32% -$155K ﹤0.01% 2923
2015
Q4 		$922K Sell
77,647
-10,480
-12% -$120K ﹤0.01% 2627
2015
Q3 		$724K Buy
88,127
+27,966
+46% +$323K ﹤0.01% 2752
2015
Q2 		$839K Buy
60,161
+29,057
+93% +$533K ﹤0.01% 2779
2015
Q1 		$747K Buy
31,104
+1,652
+6% +$37.2K ﹤0.01% 2775
2014
Q4 		$485K Sell
29,452
-2,042
-6% -$23.6K ﹤0.01% 2974
2014
Q3 		$401K Buy
31,494
+957
+3% +$14.4K ﹤0.01% 3018
2014
Q2 		$689K Buy
30,537
+19,088
+167% +$346K ﹤0.01% 2919
2014
Q1 		$323K Buy
+11,449
New +$425K ﹤0.01% 3036

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TIAA CREF Investment Management's DRNA Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 0.75% in Q1 2019, selling an estimated $8.4K and leaving 96,414 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2162.

TIAA CREF Investment Management first reported a position in DRNA in Q1 2014 and has held it in 13 quarters since. 98 funds tracked by Wall St. Rank hold DRNA as of Q1 2019.

  • TIAA CREF Investment Management held 96,414 shares of Dicerna Pharmaceuticals, Inc. worth $1.41M as of Q1 2019.
  • TIAA CREF Investment Management sold 731 Dicerna Pharmaceuticals, Inc. shares in Q1 2019, an estimated $8.4K.
  • Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2162 holding.
  • TIAA CREF Investment Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and has held it in 13 quarters since.
  • 98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.